قالب وردپرس درنا توس
Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Business https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Rep. Ocasio-Cortez hits Gilad for drug prices for HIV

Rep. Ocasio-Cortez hits Gilad for drug prices for HIV



Rep. Alexandria Occasio-Cortez, DN.Y., did not resist Thursday, questioning CEO of Truvada about the high cost of the drug used to prevent HIV with pre-exposure prophylaxis or PrEP.

"The list price is almost $ 2000 in the US, why is $ 8 in Australia?" Occasio-Cortes asked Daniel O'Clock, CEO of Gilead Sciences, after remarking that the company had earned $ 3 billion, The dollar revenue from the disposable pill in 2018

O'Dee replied that Truvada still has patent protection in the United States and the rest of the world is generic.He noted that, as announced last week, the drug will be available to the US in September 2020.

"There is no reason this would be $ 2,000 a month," Occasio-Cortez insisted on a hearing before the House Commission on the Surveillance and Reform. and there is no good reason to do so. "

RELATED: Former executive Martin Schrellie, former CEO of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc., is leaving for the office of Martin Schrellie, a former president of the pharmaceutical company Martin Schrell

16 PICTURES

following a hearing at the US Federal Court in Brooklyn, New York, United States, June 26, 2017 REUTERS / Lucas Jackson

Martin Shkreli, CEO of Turing Pharmaceuticals LLC, Center, and Attorney Evan Grebel who left the New Jersey federal court York, USA, on Thursday, December 17, 2015. Shrekley is arrested for alleged and securities fraud related to Retrophin Inc. A biotech company founded in 2011, Erebll is accused of plotting to deal with Shrekley in part of the scheme. Photographer: Peter Foley / Bloomberg via Getty Images

Martin Shkreli, CEO of Turing Pharmaceuticals LLC, leaves the federal court in New York, United States on Thursday, December 17, 2015. Shkreli is arrested on alleged securities fraud related to Retrophin Inc., a biotech company founded in 2011 Photographer: Peter Foley / Bloomberg via Getty Images

Martin Schrell, Chief Investment Officer of MSMB Capital Management, is sitting for a photo at his office in New York, on Wednesday, August 10, 2011. MSMB made an unwanted offer to absorb $ 378 million for Amag Pharmaceuticals Inc. and said he would fire the senior management if he succeeded. Photographer: Paul Tagart / Bloomberg via Getty Images *** Local Caption ** Martin Scherli

Martin Shkreli, Chief Investment Officer of MSMB Capital Management, runs a computer at his office in New York, USA on Wednesday, August 10, 2011. MSMB made an unwanted bid to acquire $ 378 million for Amag Pharmaceuticals Inc. said he would fire the senior management if he succeeded. Photographer: Paul Tagart / Bloomberg via Getty Images *** Local Inscription Martin Schrellie

Martin Schrell, Chief Investment Officer of MSMB Capital Management, is sitting behind a chessboard in New York, USA on Wednesday, August 10, 2011. MSMB made an unwanted $ 378 million takeover bid for Amag Pharmaceuticals Inc. and said he would fire the senior management if he succeeded. (L), former CEO of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc., arrives for a hearing at the US Federal Court in Brooklyn, Mich. New York, US October 14, 2016. Martin Shkrely, former CEO of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc., left after a hearing at the US Federal Court in Brooklyn, New York, US, April 26, 2017. REUTERS / Brendan McDermid

Martin Schrellie (C), former CEO of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc , arrives for a hearing at the US Federal Court in Brooklyn, New York, USA, October 14, 2016. REUTERS / Lucas Jackson

Martin Shrekley (C), former CEO of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, arrives at the Federal Court United States in New York, United States, June 6, 2016 REUTERS / Lucas Jackson [19] 659020] Martin Shrekley, a former drug executive, leaves the US Federal Court in the Brooklyn neighborhood of New York. 3 February 2016 Reuters / Brendan McDermidy

Martin Shrekley (top, R), former CEO of Turing Pharmaceuticals LLC, arrives at House Hearing Supervision and Government Reform on "Developing Market Surveillance of Medicinal Products" on the Capitol Hill in Washington, DC, Feb. 4, 2016. Martin Shkrely, former CEO of Turing Pharmaceuticals AG, left the federal court with his lawyer, Benjamin Braffman, in the Brooklyn neighborhood of New York on Thursday, June 29, 2017 Creator in 2011 Photographer: Peter F Ols / Bloomberg via Getty Images

Martin Schrell (C), CEO of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc., leaves the US Fe court following his indictment of a federal prosecution filed in Brooklyn in connection with his hedge management the MSMB Capital Management Fund and the biopharmaceutical company Retrophin Inc. in New York December 17, 2015 2016: Martin Schrellie, former CEO of Turing Pharmaceuticals LLC, responded at a meeting of the Commission on Surveillance and Government Reform on Medicines Prices in Washington, United States on Thursday, February 4 2016 is no longer with Turing and faces federal accusations of fraud, not related to a drug maker, refusing to make any comments to the committee. "I'm calling for my fifth correction on the advice of a lawyer," said Shrekley. Photographer: Pete Marovic / Bloomberg via Getty Images

Martin Schrellie, former CEO of Turing Pharmaceuticals LLC, smiles at a meeting of the Commission on Supervision and Reform of the Government Reform on Medicines Prices in Washington, , February 4, 2016. Shkreli, who is no longer with Turing and faces federal allegations of fraud, unrelated to the drug maker, has refused to comment on the commission. "I'm calling for my fifth correction on the advice of a lawyer," said Shrekley. Photographer: Pete Marovic / Bloomberg Getty Images




SCRIPT CAPITAL

OCASIO-CORRETS also claims, as activists and scientists say, the use of Truvada as a birth control pill was discovered by the US government.

"We, the public, we, the people, developed this drug, paid for this medicine, led and developed all the patents to create PrEP, and then this patent was privatized despite the fact that the patent was

, O'Day denied the accusation that the Centers for Disease Control and Prevention, part of the Ministry of Health and Human Services, have a PrEP patent. "Every employee of Gilead is proud to have invented Truvada, a medicine that can heals and prevents HIV, "he said

Nash a well-held view is that the US government does not have valid patents for the use of Truvada for pre-exposure prophylaxis, nor does it have a patent for Truvada itself, "added O'Day

The hearing came when activists stepped up pressure against Gilead, a company that commercializes and manufactures a variety of therapies and treatments for chronic illness

Members of the PrEP4All collaboration, a group of activists who insist on broad access to PrEP, and legal experts filed a petition for collective claims on Tuesday said that the country's largest HIV drug makers, including Gilead, for years have conspired to keep cheap generic drug components from popular "pill combinations" that make HIV treatment as simple as one pill a day . but that does not mean it will fall

Jamie Dornan, Melissa Barrera will star in Carmen

Occasio-Cortes hits Gilad for drug prices for HIV: "People die without cause"


Source link